Moreover, the multi-kinase inhibitor sorafenib has demonstrated the ability to modulate STAT3 activity, preventing the accumulation of atrogin-1 and Pax7 in skeletal muscle, thereby improving functional capacity and reducing fatigue in tumor-bearing animals (167). The gene discussed is FBXO32; the disease is neoplasm.